Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-06
Forminard Elizabeth Files Johnson & Johnson (JNJ) Form 4 - August 06, 2026
Forminard Elizabeth traded 25.3K JNJ shares worth $5.3M in this Form 4 filing, reported to the SEC on 2026-08-06.
- Insider
- Forminard Elizabeth
- Issuer
- Johnson & Johnson JNJ · NYSE
- Filed
- Period
- 2026-08-06
- Accession
- 0000200406-26-000169
- Source
- Official filing on sec.gov ↗
Transactions (4)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Forminard Elizabeth | 2026-08-06 | Buy | 9.3K | $131.94 | $1.2M | Direct |
| Forminard Elizabeth | 2026-08-06 | Sell | 9.3K | $257.75 | $2.4M | Direct |
| Forminard Elizabeth | 2026-08-06 | Sell | 6.6K | $255.93 | $1.7M | Direct |
| Net change | −6.6K | −$2.9M | ||||
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Track JNJ insider activity
Get alerted when Johnson & Johnson executives buy or sell their shares.